US Chronic Cough Therapeutics Market Analysis

US Chronic Cough Therapeutics Market Executive Summary

US Chronic Cough Therapeutics Market was valued at $2646 Mn in 2022 and is estimated to reach $4249 Mn in 2030, exhibiting a CAGR of 6.1% during the forecast period.

Chronic cough is a persistent cough that lasts for an extended period, typically defined as lasting for more than eight weeks. Unlike acute coughs, which are often associated with infections or other short-term conditions, chronic cough can be a symptom of an underlying and more persistent health issue. Common causes of chronic cough include respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), gastroesophageal reflux disease (GERD), postnasal drip, and certain medications. It is important to identify and address the underlying cause of chronic cough through a thorough medical evaluation, as treating the root issue is crucial for effective management. Chronic cough can significantly impact an individual's quality of life and may require a multidisciplinary approach involving healthcare professionals such as pulmonologists, gastroenterologists, or ear, nose, and throat (ENT) specialists for comprehensive care.

In the US, the prevalence of chronic cough among adults is estimated to be around 5.0%, accounting for approximately 12.3 Mn individuals. On a global scale, the prevalence of chronic cough is reported to be higher at 9.6%. The impact of chronic cough extends beyond its prevalence, contributing to a diminished health-related quality of life, heightened levels of anxiety, and impaired work productivity. Chronic cough is more prevalent in specific demographic groups, with older adults being at a higher risk, as age emerges as a significant factor. Additionally, individuals who smoke tobacco are significantly more prone to developing chronic cough. Furthermore, those with existing respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and postnasal drip also exhibit an increased likelihood of experiencing chronic cough.

GlaxoSmithKline (GSK) introduced an enhanced formulation of their Theraflu Cold & Cough Severe product in the US. This updated version incorporates a higher dose of dextromethorphan, aiming to provide more robust suppression of cough symptoms.

Market Dynamics

Market Growth Drivers

Aging Population: As per the 2020 Census, the elderly demographic saw a significant rise of 50.9 Mn individuals, escalating from 4.9 Mn in 1920 to 55.8 Mn in 2020. This reflects a growth rate of approximately 1,000%, nearly 5 times higher than that of the overall population. With the aging population, the susceptibility to chronic respiratory conditions such as COPD and asthma, leading to persistent coughing, also elevates.

Rising Air Pollution: A report by the American Lung Association reveals that over 119 Mn residents in the US, roughly 1 in 4 people, reside in areas where air pollution poses health risks and may reduce their lifespan. The US Environmental Protection Agency notes a significant reduction of 78% in emissions of outdoor air pollutants since 1970. Exposure to air pollution, encompassing factors like cigarette smoke and particulate matter, stands as a notable risk element for the onset of chronic cough.

Increased Awareness and Diagnosis: Rising awareness and enhanced diagnostic methods contribute to an increased number of individuals seeking treatment for chronic cough as a recognized medical condition.

Market Restraints

Limited Effectiveness of Current OTC Medications: While over-the-counter (OTC) cough suppressants offer momentary relief, they frequently fall short in effectively addressing chronic cough symptoms over extended durations. This discontentment acts as an impediment to the growth of the market.

Cost and Accessibility Barriers: The high costs associated with cutting-edge diagnostic tools and modern cough treatments can restrict accessibility for certain patients, contributing to healthcare disparities. Limited insurance coverage for cough treatment may compel patients to opt for less effective or more affordable alternatives.

Misinformation and Overuse of OTC Medications: Public misconceptions about chronic cough, coupled with self-medication using OTC medications, can result in overuse and potential adverse effects. Insufficient awareness regarding the importance of seeking professional diagnosis and appropriate treatment further complicates the issue.

Healthcare Policies and Regulatory Landscape

In the US, diverse authorities are responsible for overseeing the regulatory framework and healthcare policies associated with therapeutic drugs. The Food and Drug Administration (FDA), as a governmental body, plays a pivotal role in conducting comprehensive assessments before a product enters the market, monitoring its safety post-market, and granting approval for new pharmaceuticals. Specifically, the FDA's Centre for Drug Evaluation and Research (CDER) manages pre-market evaluations, drug regulation, and the formulation of guidelines for drug development. The Drug Enforcement Administration (DEA), within the U.S. Department of Justice, is responsible for enforcing regulations to combat the misuse and diversion of prohibited narcotics. Additionally, the Centres for Medicare & Medicaid Services (CMS) wield significant influence over a substantial portion of the population's access to pharmaceuticals by overseeing reimbursement policies for medications covered by Medicare and Medicaid.

Competitive Landscape

Key Players

• GlaxoSmithKline (GSK)
• Pfizer
• McNeil Consumer Healthcare (Johnson & Johnson)
• Procter & Gamble (P&G)
• Reckitt Benckiser Group
• Perrigo Company
• Medtech Products Inc.
• Bionpharma Inc.
• A. Vogel Canada Inc.
• Jamieson Laboratories